ID28070A - Kalsium (3s) tetrahidro-3-furanil (1s,2r)-3-((4-aminofenil) sulfonil) (isobutil) amino)-1-benzil-2-(fosfonooksi) propilkarbamat - Google Patents

Kalsium (3s) tetrahidro-3-furanil (1s,2r)-3-((4-aminofenil) sulfonil) (isobutil) amino)-1-benzil-2-(fosfonooksi) propilkarbamat

Info

Publication number
ID28070A
ID28070A IDW20010145A ID20010145A ID28070A ID 28070 A ID28070 A ID 28070A ID W20010145 A IDW20010145 A ID W20010145A ID 20010145 A ID20010145 A ID 20010145A ID 28070 A ID28070 A ID 28070A
Authority
ID
Indonesia
Prior art keywords
propilcarbamate
phosphonoxysi
aminofenil
isobutil
furanil
Prior art date
Application number
IDW20010145A
Other languages
English (en)
Indonesian (id)
Inventor
Ian Gordan Armitage
Andrew David Searle
Herdev Singh
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ID28070A publication Critical patent/ID28070A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IDW20010145A 1998-07-18 1999-07-15 Kalsium (3s) tetrahidro-3-furanil (1s,2r)-3-((4-aminofenil) sulfonil) (isobutil) amino)-1-benzil-2-(fosfonooksi) propilkarbamat ID28070A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
ID28070A true ID28070A (id) 2001-05-03

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010145A ID28070A (id) 1998-07-18 1999-07-15 Kalsium (3s) tetrahidro-3-furanil (1s,2r)-3-((4-aminofenil) sulfonil) (isobutil) amino)-1-benzil-2-(fosfonooksi) propilkarbamat

Country Status (47)

Country Link
US (3) US6514953B1 (es)
EP (2) EP1098898B1 (es)
JP (1) JP3437553B2 (es)
KR (1) KR100694721B1 (es)
CN (1) CN1188422C (es)
AP (1) AP2001002039A0 (es)
AR (1) AR019388A1 (es)
AT (1) ATE229964T1 (es)
AU (1) AU766056B2 (es)
BG (1) BG105253A (es)
BR (1) BRPI9912156B8 (es)
CA (1) CA2337857C (es)
CO (1) CO5090836A1 (es)
CZ (1) CZ300447B6 (es)
DE (1) DE69904600T2 (es)
DK (1) DK1098898T3 (es)
DZ (1) DZ2845A1 (es)
EA (1) EA003191B1 (es)
EE (1) EE200100038A (es)
ES (1) ES2189450T3 (es)
GB (1) GB9815567D0 (es)
GC (1) GC0000105A (es)
GE (1) GEP20033030B (es)
GT (1) GT199900111A (es)
HR (1) HRP20010046A2 (es)
HU (1) HU229700B1 (es)
ID (1) ID28070A (es)
IL (1) IL140824A (es)
IS (1) IS5808A (es)
JO (1) JO2114B1 (es)
MA (1) MA26660A1 (es)
MY (1) MY122323A (es)
NO (1) NO329676B1 (es)
NZ (1) NZ509291A (es)
OA (1) OA11706A (es)
PA (1) PA8477801A1 (es)
PE (1) PE20000869A1 (es)
PL (1) PL195736B1 (es)
PT (1) PT1098898E (es)
SK (1) SK285311B6 (es)
SV (1) SV1999000096A (es)
TN (1) TNSN99145A1 (es)
TR (1) TR200100111T2 (es)
TW (1) TWI245770B (es)
WO (1) WO2000004033A1 (es)
YU (1) YU3401A (es)
ZA (1) ZA200100417B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
BR0014602A (pt) * 1999-10-06 2002-06-11 Tibotec Pharm Ltd Hexaidrofluoro'2,3-bifuran-3-il-n-{3'(1,3-benzodioxol- 5ilsulfonil)(isobutil)amino-1 -benzil-2-hidroxipropil}carbamato como inibidor da protease retroviral
ATE285821T1 (de) * 1999-10-08 2005-01-15 Affinium Pharm Inc Fab i inhibitoren
US7049310B2 (en) * 2001-04-06 2006-05-23 Affinium Pharmaceuticals, Inc. Fab I inhibitors
EA008775B1 (ru) 2002-04-26 2007-08-31 Джилид Сайэнс, Инк. Ингибиторы протеазы вич для лечения инфекции вич и фармацевтическая композиция
JP4859460B2 (ja) 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． ヘテロ環化合物、その製造方法および治療におけるその使用
WO2004082586A2 (en) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7417055B2 (en) 2003-04-25 2008-08-26 Gilead Sciences, Inc. Kinase inhibitory phosphonate analogs
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
PT1670448E (pt) * 2003-09-30 2008-02-11 Tibotec Pharm Ltd Sulfonamidas inibidoras de hcv
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
CA2543294A1 (en) 2003-10-24 2005-05-26 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
AU2004309418B2 (en) 2003-12-22 2012-01-19 Gilead Sciences, Inc. 4'-substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
CA2568914C (en) 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
JP2008508291A (ja) 2004-07-27 2008-03-21 ギリアード サイエンシーズ， インコーポレイテッド 抗ｈｉｖ剤としてのヌクレオシドホスホネート結合体
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
US8318720B2 (en) 2006-07-20 2012-11-27 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as Fab I inhibitors
EP2125802A4 (en) 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
KR101518079B1 (ko) 2007-03-12 2015-05-06 넥타르 테라퓨틱스 올리고머-프로테아제 억제제 컨주게이트
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
EP2307435B1 (en) 2008-07-08 2012-06-13 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
ES2791524T3 (es) 2009-04-03 2020-11-04 Ocera Therapeutics Inc Fenilacetato de L-ornitina y métodos de elaboración del mismo
US20120135965A1 (en) * 2009-05-20 2012-05-31 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
EP3517110A1 (en) 2009-06-08 2019-07-31 UCL Business PLC Treatment of inflammation using l-ornithine phenylacetate
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
WO2011001383A1 (en) * 2009-06-30 2011-01-06 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
US9085592B2 (en) 2009-09-16 2015-07-21 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
EP2507250A1 (en) * 2010-01-07 2012-10-10 Pliva Hrvastka D.O.O. Solid state forms of fosamprenavir calcium salt and process for preparation thereof
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
WO2011158259A1 (en) * 2010-06-18 2011-12-22 Matrix Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
WO2012032389A2 (en) 2010-09-10 2012-03-15 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
US8993786B2 (en) 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
IN2012DE00082A (es) 2012-01-10 2015-05-01 Council Scient Ind Res
WO2013190384A1 (en) 2012-06-19 2013-12-27 Affinium Pharmaceuticals, Inc. Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
BR112017010761B1 (pt) 2014-11-24 2022-10-18 Ucl Business Plc Tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
CA2995823A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
RS61312B1 (sr) 2016-02-26 2021-02-26 Debiopharm Int Sa Lek za lečenje infekcija dijabetskog stopala
EP3621947A4 (en) 2017-05-11 2021-03-10 Ocera Therapeutics, Inc. L-ORNITHINE PHENYLACETATE MANUFACTURING PROCESSES
EP3661937B1 (en) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
CN116327781A (zh) 2019-02-14 2023-06-27 德彪药业国际股份公司 阿法比星制剂及其制备方法
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
PL341762A1 (en) * 1997-12-24 2001-05-07 Vertex Pharma Precursors of aspartil protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
WO2000018384A2 (en) * 1998-09-28 2000-04-06 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
US6147095A (en) * 1998-11-04 2000-11-14 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
EP1242426B1 (en) * 1999-11-24 2007-10-31 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors

Also Published As

Publication number Publication date
EP1098898A1 (en) 2001-05-16
NZ509291A (en) 2003-05-30
BR9912156A (pt) 2001-04-10
NO20010282D0 (no) 2001-01-17
TWI245770B (en) 2005-12-21
DK1098898T3 (da) 2003-04-07
AR019388A1 (es) 2002-02-13
EA200100053A1 (ru) 2001-08-27
SK762001A3 (en) 2001-10-08
GT199900111A (es) 2001-01-05
AU766056B2 (en) 2003-10-09
CO5090836A1 (es) 2001-10-30
IL140824A0 (en) 2002-02-10
KR100694721B1 (ko) 2007-03-15
CZ300447B6 (cs) 2009-05-20
TNSN99145A1 (fr) 2005-11-10
JO2114B1 (en) 2000-05-21
GEP20033030B (en) 2003-07-25
PA8477801A1 (es) 2000-05-24
NO20010282L (no) 2001-03-07
IL140824A (en) 2004-09-27
SV1999000096A (es) 2000-07-06
PT1098898E (pt) 2003-04-30
HUP0103432A3 (en) 2003-01-28
EE200100038A (et) 2002-06-17
AP2001002039A0 (en) 2001-03-31
JP2003521447A (ja) 2003-07-15
OA11706A (en) 2005-01-13
IS5808A (is) 2001-01-12
ZA200100417B (en) 2002-02-27
US20030096795A1 (en) 2003-05-22
DZ2845A1 (fr) 2003-12-01
CN1188422C (zh) 2005-02-09
CA2337857C (en) 2011-01-25
BRPI9912156B8 (pt) 2021-05-25
NO329676B1 (no) 2010-11-29
PL195736B1 (pl) 2007-10-31
MY122323A (en) 2006-04-29
EP1240903A2 (en) 2002-09-18
US6514953B1 (en) 2003-02-04
BG105253A (en) 2001-12-29
EP1098898B1 (en) 2002-12-18
WO2000004033A1 (en) 2000-01-27
CZ2001219A3 (cs) 2001-07-11
BRPI9912156B1 (pt) 2016-07-26
HK1034261A1 (en) 2001-10-19
JP3437553B2 (ja) 2003-08-18
GB9815567D0 (en) 1998-09-16
CN1324363A (zh) 2001-11-28
CA2337857A1 (en) 2000-01-27
HRP20010046A2 (en) 2002-02-28
AU5037999A (en) 2000-02-07
MA26660A1 (fr) 2004-12-20
HUP0103432A2 (hu) 2002-04-29
DE69904600D1 (de) 2003-01-30
ATE229964T1 (de) 2003-01-15
TR200100111T2 (tr) 2002-02-21
PE20000869A1 (es) 2000-09-08
ES2189450T3 (es) 2003-07-01
EA003191B1 (ru) 2003-02-27
GC0000105A (en) 2005-06-29
PL345620A1 (en) 2002-01-02
YU3401A (sh) 2005-06-10
SK285311B6 (sk) 2006-10-05
EP1240903A3 (en) 2003-02-12
HU229700B1 (en) 2014-05-28
DE69904600T2 (de) 2003-11-13
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
ID28070A (id) Kalsium (3s) tetrahidro-3-furanil (1s,2r)-3-((4-aminofenil) sulfonil) (isobutil) amino)-1-benzil-2-(fosfonooksi) propilkarbamat
DZ2285A1 (fr) Inhibiteurs de protéase de la cystéine.
NO982097D0 (no) Peptider
NO982098L (no) Peptider
FI102434B (fi) Kahden taajuuden antenni
TR970073A2 (tr) Alfa adrenerjik resentör antagonistleri olarak pirimidindion pirimidintrion,triazindion, tetrahidrokinazolindion türevleri.
DE69838000D1 (de) Weiche,bifokale kontaktlinse
ITBO980146A0 (it) Pacchetto per sigarette.
EA200000208A1 (ru) Иммуномодулятор с антимикробной и антимикобактериальной активностью, способ его получения и лекарственный препарат для лечения микобактериозов, хронических неспецифических заболеваний легких, заболеваний, передающихся половым путем, и иммунодефицита на их основе
FI972384A7 (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-termin aalisia sulfonyyli- tai amidinosulfonyyliryhmiä
DE69933647D1 (de) Rekombinante lysophosphatidsäure - phosphatase.
NO963526D0 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)-etylÅ-2,2-difenylacetamid
DE59806925D1 (de) Satbilisierter, kubischer, flexibler Behälter
ID18458A (id) Pembuatan alifatik alfa, omega-amino nitril
FR2763498B1 (fr) Endoscope, en particulier mediastinoscope
DZ2815A1 (fr) Inhibiteurs de protéase.
IT1312093B1 (it) Condimento confezionato.
NL1008191A1 (nl) Afdichting.
ES1047984Y (es) Corchete de ortodoncia.
NL1012028A1 (nl) Aminozuursequentie.
IT1303333B1 (it) Sottopiede per calzature.
SI1098898T1 (en) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-(((4-aminophenyl) sulfonyl) (isobutyl) amino) -1-benzyl-2- (phosphonooxy) propylcarbamate
ES1036589Y (es) Maquina surqueadora estanqueadora.
IT245874Y1 (it) Sostegno-espositore per calzature.
SE9802536D0 (sv) Novel peptides